[Immunohistochemical profile of renal cell tumours].
[Immunohistochemical profile of renal cell tumours].
复制标题
DOI：
10.1016/j.patol.2019.02.004
复制
发表时间：
2019-10-01
期刊：
影响因子：
--
通讯作者：
Niebles De la Hoz, Maria Camila
中科院分区：
文献类型：
--
作者：
Gutierrez Olivares, Victor Manuel;Gonzalez Torres, Luz Mery;Niebles De la Hoz, Maria Camila
背景：肾癌是世界上最常见的 10 种癌症之一，每年约有 270,000 例确诊病例，116,000 人死于该病。大约 90% 的实体肾肿瘤是肾细胞癌。哥伦比亚每年的发病率约为 500-1000 例。 目的：通过使用免疫组织化学标记物来表征在波哥大圣何塞医院 (HSJ) 和波哥大圣何塞大学婴儿医院 (HUISJ) 病理实验室诊断的不同肾细胞肿瘤。 材料和方法：对所有肾细胞的苏木精和伊红以及免疫组织化学切片进行回顾性分析2014 年 1 月至 2016 年 12 月，波哥大 HSJ 和 HUISJ 病理实验室诊断出 18 岁以上女性和男性癌症。使用的抗体为：CAIX（碳酸酐酶）、RCC（肾细胞癌标记物）、波形蛋白、CD10、CK7、TFE3（与 IGHM 增强子 3 结合的转录因子）、CD117、CD15、CK20、钙粘蛋白和 PAX8。通过卡方检验的单变量和双变量分析报告不同标记物的绝对和相对频率。 结果：比较统计显着性标记物的表达，透明细胞癌 (CRCC) 与 RCC 嫌色细胞 (ChRCC) 的免疫谱结果如下：CRCC 阳性标记物：CAIX、波形蛋白、CD15、CD10、钙粘蛋白和阴性标记物：CK7、CD117； ChRCC 阳性标记物：CK7、CD117、CD10、钙粘蛋白和 CAIX 阴性标记物：波形蛋白、CD15。两种肿瘤中的 PAX8 标记物均呈阳性或阴性。结论：五种标记物证明了区分 CRCC 和 ChRCC 组织学亚型的实用性和有效性。我们建议组合标志物（CAIX、CK7、波形蛋白、CD15 和 CD117）来鉴别诊断 CRCC 与 ChRCC。
CONTEXT: Kidney cancer is among the 10 most frequent cancers in the world, each year about 270,000 cases are diagnosed and 116,000 people die from the disease. Approximately 90% of all solid kidney neoplasms are renal cell carcinomas. The incidence in Colombia is approximately 500-1000 cases per year.OBJECTIVE: To characterize through the use of immunohistochemical markers the different renal cell tumours diagnosed in the pathology laboratory of the San Jose Hospital (HSJ) and the University Infantil Hospital of San Jose (HUISJ) in Bogota.MATERIALS AND METHODS: A retrospective review was performed of the Hematoxylin and eosin and immunohistochemistry slides of all renal cell carcinomas diagnosed in women and men over 18 years in the pathology laboratory of the HSJ and the HUISJ from Bogota from January 2014 to December 2016. The antibodies used were: CAIX (carbonic anhydrase), RCC (renal cell carcinoma marker), vimentin, CD10, CK7, TFE3 (transcription factor binding to IGHM enhancer 3), CD117, CD15, CK20, cadherin and PAX8. Absolute and relative frequencies of the different markers were reported through univariate and bivariate analyses with a chi-square test.RESULTS: Comparing the expression of statistically significant markers, an immunoprofile resulted for clear cell carcinoma (CRCC) versus RCC chromophobe (ChRCC) as follows: CRCC positive markers: CAIX, vimentin, CD15, CD10, cadherin and negative markers: CK7, CD117; ChRCC positive markers: CK7, CD117, CD10, cadherin and CAIX negative markers: vimentin, CD15. The PAX8 marker was positive or negative in both tumors.CONCLUSION: Five markers demonstrated utility and validity to differentiate between histological subtypes of CRCC and ChRCC. We propose the combination of markers (CAIX, CK7, vimentin, CD15 and CD117) for the differential diagnosis between CRCC versus ChRCC.